Alfacalcidol
Alfacalcidol is an analogue of Vitamin D and a potent inhibitor of bone resorption [1].
Alfacalcidol has been revealed to play a part in bone and mineral homeostasis via binding to the VDR (vitamin D receptor) in calcium-related target organs, such as intestine, bone, kidney and parathyroid gland. In addition, in a high bone-turnover state after OVX, Alfacalcidol has been reported to inhibit osteoclastic bone resorption at pharmacological doses that do not cause hypercalcemia. Apart from these, Alfacalcidol has shown the stimulative effect to the bone formation. Furthermore, Alfacalcidol has been found to enhance bone mass and bone strength at given serum and urinary calcium levels in the OVX model.
References:
[1] Shiraishi A1, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res. 2000 Apr;15(4):770-9.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 400.65 |
| Cas No. | 41294-56-8 |
| Formula | C27H44O2 |
| Solubility | insoluble in H2O; ≥20.05 mg/mL in DMSO; ≥21.6 mg/mL in EtOH |
| Chemical Name | (1R,3S,5E)-5-[(2Z)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol |
| SDF | Download SDF |
| Canonical SMILES | CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Animal experiment [1]: | |
|
Animal models |
ovariectomized rat model of osteoporosis |
|
Preparation method |
The solubility of this compound in DMSO is >20.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Dosage form |
0.05, 0.1, and 0.2 μg/kg; orally administered; five times a week for 12 weeks |
|
Application |
In ovariectomized rat model of osteoporosis, Alfacalcidol inhibited osteoclastic bone resorption in a dose-dependent way and maintained or even stimulated bone formation. Alfacalcidol increased bone mineral density and improved mechanical strength more effectively than 17b-estradiol. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Shiraishi A1, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res. 2000 Apr;15(4):770-9. | |
Quality Control & MSDS
- View current batch:
Chemical structure
